|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GTF3C5 |
Gene summary for GTF3C5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GTF3C5 | Gene ID | 9328 |
| Gene name | general transcription factor IIIC subunit 5 | |
| Gene Alias | TFIIIC63 | |
| Cytomap | 9q34.13 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9Y5Q8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9328 | GTF3C5 | LZE4T | Human | Esophagus | ESCC | 6.31e-04 | 3.19e-01 | 0.0811 |
| 9328 | GTF3C5 | LZE7T | Human | Esophagus | ESCC | 1.73e-10 | 7.14e-01 | 0.0667 |
| 9328 | GTF3C5 | LZE8T | Human | Esophagus | ESCC | 1.88e-17 | 6.10e-01 | 0.067 |
| 9328 | GTF3C5 | LZE20T | Human | Esophagus | ESCC | 8.11e-08 | 2.75e-01 | 0.0662 |
| 9328 | GTF3C5 | LZE22D1 | Human | Esophagus | HGIN | 7.18e-05 | 1.60e-01 | 0.0595 |
| 9328 | GTF3C5 | LZE24T | Human | Esophagus | ESCC | 3.39e-15 | 4.05e-01 | 0.0596 |
| 9328 | GTF3C5 | P1T-E | Human | Esophagus | ESCC | 1.02e-11 | 5.32e-01 | 0.0875 |
| 9328 | GTF3C5 | P2T-E | Human | Esophagus | ESCC | 3.18e-41 | 7.01e-01 | 0.1177 |
| 9328 | GTF3C5 | P4T-E | Human | Esophagus | ESCC | 4.17e-14 | 4.89e-01 | 0.1323 |
| 9328 | GTF3C5 | P5T-E | Human | Esophagus | ESCC | 1.44e-19 | 3.34e-01 | 0.1327 |
| 9328 | GTF3C5 | P8T-E | Human | Esophagus | ESCC | 3.24e-40 | 7.24e-01 | 0.0889 |
| 9328 | GTF3C5 | P9T-E | Human | Esophagus | ESCC | 4.97e-11 | 2.42e-01 | 0.1131 |
| 9328 | GTF3C5 | P10T-E | Human | Esophagus | ESCC | 1.17e-26 | 5.68e-01 | 0.116 |
| 9328 | GTF3C5 | P11T-E | Human | Esophagus | ESCC | 2.09e-13 | 6.81e-01 | 0.1426 |
| 9328 | GTF3C5 | P12T-E | Human | Esophagus | ESCC | 3.51e-27 | 4.25e-01 | 0.1122 |
| 9328 | GTF3C5 | P15T-E | Human | Esophagus | ESCC | 1.24e-30 | 7.27e-01 | 0.1149 |
| 9328 | GTF3C5 | P16T-E | Human | Esophagus | ESCC | 1.03e-15 | 3.00e-01 | 0.1153 |
| 9328 | GTF3C5 | P17T-E | Human | Esophagus | ESCC | 2.04e-14 | 5.96e-01 | 0.1278 |
| 9328 | GTF3C5 | P19T-E | Human | Esophagus | ESCC | 8.94e-08 | 5.52e-01 | 0.1662 |
| 9328 | GTF3C5 | P20T-E | Human | Esophagus | ESCC | 4.70e-08 | 2.23e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00605379 | Esophagus | HGIN | muscle tissue development | 76/2587 | 403/18723 | 2.67e-03 | 2.63e-02 | 76 |
| GO:00063523 | Esophagus | HGIN | DNA-templated transcription, initiation | 30/2587 | 130/18723 | 2.86e-03 | 2.79e-02 | 30 |
| GO:00147068 | Esophagus | HGIN | striated muscle tissue development | 72/2587 | 384/18723 | 3.94e-03 | 3.56e-02 | 72 |
| GO:00063833 | Esophagus | ESCC | transcription by RNA polymerase III | 41/8552 | 46/18723 | 7.69e-10 | 1.90e-08 | 41 |
| GO:00987812 | Esophagus | ESCC | ncRNA transcription | 45/8552 | 56/18723 | 1.05e-07 | 1.72e-06 | 45 |
| GO:000635211 | Esophagus | ESCC | DNA-templated transcription, initiation | 86/8552 | 130/18723 | 1.88e-06 | 2.19e-05 | 86 |
| GO:00093032 | Esophagus | ESCC | rRNA transcription | 28/8552 | 34/18723 | 1.21e-05 | 1.12e-04 | 28 |
| GO:006053716 | Esophagus | ESCC | muscle tissue development | 211/8552 | 403/18723 | 3.84e-03 | 1.56e-02 | 211 |
| GO:001470615 | Esophagus | ESCC | striated muscle tissue development | 197/8552 | 384/18723 | 1.46e-02 | 4.74e-02 | 197 |
| GO:0006352 | Liver | HCC | DNA-templated transcription, initiation | 78/7958 | 130/18723 | 4.19e-05 | 4.11e-04 | 78 |
| GO:0009303 | Liver | HCC | rRNA transcription | 25/7958 | 34/18723 | 2.42e-04 | 1.81e-03 | 25 |
| GO:0006383 | Liver | HCC | transcription by RNA polymerase III | 31/7958 | 46/18723 | 5.67e-04 | 3.61e-03 | 31 |
| GO:0098781 | Liver | HCC | ncRNA transcription | 33/7958 | 56/18723 | 9.64e-03 | 3.63e-02 | 33 |
| GO:00063832 | Oral cavity | OSCC | transcription by RNA polymerase III | 34/7305 | 46/18723 | 1.61e-06 | 2.11e-05 | 34 |
| GO:00987811 | Oral cavity | OSCC | ncRNA transcription | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
| GO:00063522 | Oral cavity | OSCC | DNA-templated transcription, initiation | 74/7305 | 130/18723 | 2.56e-05 | 2.39e-04 | 74 |
| GO:00093031 | Oral cavity | OSCC | rRNA transcription | 24/7305 | 34/18723 | 1.89e-04 | 1.28e-03 | 24 |
| GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
| GO:00147067 | Oral cavity | OSCC | striated muscle tissue development | 174/7305 | 384/18723 | 6.45e-03 | 2.40e-02 | 174 |
| GO:00063831 | Oral cavity | LP | transcription by RNA polymerase III | 20/4623 | 46/18723 | 4.03e-03 | 2.61e-02 | 20 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| GTF3C5 | PERI | Thyroid | Healthy | IL11,ELOVL3,NTN1, etc. | 5.20e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GTF3C5 | SNV | Missense_Mutation | rs140794229 | c.519N>A | p.Phe173Leu | p.F173L | Q9Y5Q8 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
| GTF3C5 | SNV | Missense_Mutation | c.1453G>C | p.Glu485Gln | p.E485Q | Q9Y5Q8 | protein_coding | tolerated(0.21) | benign(0.067) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| GTF3C5 | insertion | Frame_Shift_Ins | novel | c.1530_1531insGGGTGCCCGTCAAACTACAGCTTCCCTGGGGGGCCTCCACCCCATAC | p.Ser511GlyfsTer50 | p.S511Gfs*50 | Q9Y5Q8 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| GTF3C5 | SNV | Missense_Mutation | novel | c.970N>T | p.Arg324Cys | p.R324C | Q9Y5Q8 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A1MQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| GTF3C5 | SNV | Missense_Mutation | c.65G>A | p.Arg22Gln | p.R22Q | Q9Y5Q8 | protein_coding | tolerated(0.07) | benign(0.018) | TCGA-EA-A3QD-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| GTF3C5 | SNV | Missense_Mutation | c.469G>A | p.Glu157Lys | p.E157K | Q9Y5Q8 | protein_coding | tolerated(0.22) | benign(0.122) | TCGA-Q1-A6DT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| GTF3C5 | SNV | Missense_Mutation | c.731N>G | p.Asn244Ser | p.N244S | Q9Y5Q8 | protein_coding | tolerated(0.05) | probably_damaging(0.919) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| GTF3C5 | SNV | Missense_Mutation | c.277N>G | p.Arg93Gly | p.R93G | Q9Y5Q8 | protein_coding | deleterious(0.01) | benign(0.023) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| GTF3C5 | SNV | Missense_Mutation | rs201605177 | c.905G>A | p.Arg302Gln | p.R302Q | Q9Y5Q8 | protein_coding | deleterious(0.02) | probably_damaging(0.978) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GTF3C5 | SNV | Missense_Mutation | rs745823251 | c.1387C>T | p.Arg463Trp | p.R463W | Q9Y5Q8 | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-AZ-6600-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | cpt-11 | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |